Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

David Cooper

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Calmy Alexandra; Fux Christoph A; Norris Richard; Vallier Nathalie; Delhumeau Cécile; Samaras Katherine; Hesse Karl; Hirschel Bernard; Cooper David A; Carr Andrew
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
Elliott Julian H; Vohith Khol; Saramony Sarun; Savuth Chin; Dara Chan; Sarim Chel; Huffam Sarah; Oelrichs Robert; Sophea Pouv; Saphonn Vonthanak; Kaldor John; Cooper David A; Chhi Vun Mean; French Martyn A
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.
Martin Allison; Bloch Mark; Amin Janaki; Baker David; Cooper David A; Emery Sean; Carr Andrew
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of David Cooper (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Calmy Alexandra; Fux Christoph A; Norris Richard; Vallier Nathalie; Delhumeau Cécile; Samaras Katherine; Hesse Karl; Hirschel Bernard; Cooper David A; Carr Andrew
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
The Journal of infectious diseases 2009;200(11):1746-54.
2009: Elliott Julian H; Vohith Khol; Saramony Sarun; Savuth Chin; Dara Chan; Sarim Chel; Huffam Sarah; Oelrichs Robert; Sophea Pouv; Saphonn Vonthanak; Kaldor John; Cooper David A; Chhi Vun Mean; French Martyn A
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.
The Journal of infectious diseases 2009;200(11):1736-45.
2009: Martin Allison; Bloch Mark; Amin Janaki; Baker David; Cooper David A; Emery Sean; Carr Andrew
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(10):1591-601.
2009: Zaunders John J; Munier Mee Ling; Seddiki Nabila; Pett Sarah; Ip Susanna; Bailey Michelle; Xu Yin; Brown Kai; Dyer Wayne B; Kim Min; de Rose Robert; Kent Stephen J; Jiang Lele; Breit Samuel N; Emery Sean; Cunningham Anthony L; Cooper David A; Kelleher Anthony D
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).
Journal of immunology (Baltimore, Md. : 1950) 2009;183(4):2827-36.
2009: Chang J Judy; Sirivichayakul Sunee; Avihingsanon Anchalee; Thompson Alex J V; Revill Peter; Iser David; Slavin John; Buranapraditkun Supranee; Marks Pip; Matthews Gail; Cooper David A; Kent Stephen J; Cameron Paul U; Sasadeusz Joe; Desmond Paul; Locarnini Stephen; Dore Gregory J; Ruxrungtham Kiat; Lewin Sharon R
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.
Journal of virology 2009;83(15):7649-58.
2009: Boyd Mark; Emery Sean; Cooper David A
Antiretroviral roll-out: the problem of second-line therapy.
Lancet 2009;374(9685):185-6.
2009: Byakwaga Helen; Murray John M; Petoumenos Kathy; Kelleher Anthony D; Law Matthew G; Boyd Mark A; Emery Sean; Mallon Patrick W; Cooper David A
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
AIDS research and human retroviruses 2009;25(6):756-76.
2009: Avihingsanon A; van der Lugt J; Kerr S J; Gorowara M; Chanmano S; Ohata P; Lange J; Cooper D A; Phanuphak P; Burger D M; Ruxrungtham K
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
Clinical pharmacology and therapeutics 2009;85(4):402-8.
2009: Carey D; Baker D; Petoumenos K; Chuah J; Rogers G D; Watson J; Cooper D A; Emery S; Carr A;
Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
HIV medicine 2009;10(3):163-72.
2009: Byakwaga H; Zhou J; Petoumenos K; Law M G; Boyd M A; Emery S; Cooper D A; Mallon P W
Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.
HIV medicine 2009;10(3):143-51.
2009: Falster Kathleen; Petoumenos Kathy; Chuah John; Mijch Anne; Mulhall Brian; Kelly Mark; Cooper David A;
Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):307-13.
2009: Seddiki Nabila; Sasson Sarah C; Santner-Nanan Brigitte; Munier Meeling; van Bockel David; Ip Susanna; Marriott Debbie; Pett Sarah; Nanan Ralph; Cooper David A; Zaunders John J; Kelleher Anthony D
Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease.
European journal of immunology 2009;39(2):391-403.
2009: Pett Sarah L; McCarthy Michael C; Cooper David A; MacRae Karen; Tendolkar Amol; Norris Richard; Strizki Julie M; Williams Kenneth M; Emery Sean
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
Antiviral therapy 2009;14(1):111-5.
2008: Mallon Patrick W G; Sedwell Rebecca; Rogers Gary; Nolan David; Unemori Patrick; Hoy Jennifer; Samaras Katherine; Kelleher Anthony; Emery Sean; Cooper David A; Carr Andrew;
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
The Journal of infectious diseases 2008;198(12):1794-803.
2008: Boesecke Christoph; Cooper David A
Toxicity of HIV protease inhibitors: clinical considerations.
Current opinion in HIV and AIDS 2008;3(6):653-9.
2008: Matthews Gail V; Avihingsanon Anchalee; Lewin Sharon R; Amin Janaki; Rerknimitr Rungsun; Petcharapirat Panusit; Marks Pip; Sasadeusz Joe; Cooper David A; Bowden Scott; Locarnini Stephen; Ruxrungtham Kiat; Dore Gregory J
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Hepatology (Baltimore, Md.) 2008;48(4):1062-9.
2008: Ananworanich Jintanat; Puthanakit Thanyawee; Saphonn Vonthanak; Cooper David A; Ruxrungtham Kiat
Lessons from a multicentre paediatric HIV trial.
Lancet 2008;372(9636):356-7.
2008: Suzuki Kazuo; Juelich Torsten; Lim Heidi; Ishida Takaomi; Watanebe Toshiki; Cooper David A; Rao Sudha; Kelleher Anthony D
Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region.
The Journal of biological chemistry 2008;283(34):23353-63.
2008: Voirin N; Routy J-P; Smith D; Baratin D; Trépo C; Cotte L; Touraine J-L; Livrozet J-M; Cooper D A; Ritter J; André P; Vanhems P
Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome.
HIV medicine 2008;9(6):440-4.
2008: Wilson David P; Law Matthew G; Grulich Andrew E; Cooper David A; Kaldor John M
Relation between HIV viral load and infectiousness: a model-based analysis.
Lancet 2008;372(9635):314-20.
2008: Cooper David A
Life and death in the cART era.
Lancet 2008;372(9635):266-7.
2008: Cooper David A; Steigbigel Roy T; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Teppler Hedy; Nguyen Bach-Yen;
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Steigbigel Roy T; Cooper David A; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Nguyen Bach-Yen; Teppler Hedy;
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2008: van der Lugt Jasper; Autar Reshma Saskia; Ubolyam Sasiwimol; Garcia Evian Fernandez; Sankote Jongkol; Avihingsanon Anchalee; Chuenyam Theshinee; Cooper David A; Lange Joep; Phanuphak Praphan; Wit Ferdinand; Ruxrungtham Kiat; Burger David;
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
The Journal of antimicrobial chemotherapy 2008;61(5):1145-53.
2008: Lim Heidi G W; Suzuki Kazuo; Cooper David A; Kelleher Anthony D
Promoter-targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(3):565-70.
2008: Lewin Sharon R; Murray John M; Solomon Ajantha; Wightman Fiona; Cameron Paul U; Purcell Damian J; Zaunders John J; Grey Pat; Bloch Mark; Smith Don; Cooper David A; Kelleher Anthony D
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2008;47(2):140-47.
2008: Calmy A; Carey D; Mallon P W G; Wand H; Law M; Cooper D A; Carr A;
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
HIV medicine 2008;9(2):101-10.
2008: Ananworanich Jintanat; Kosalaraksa Pope; Siangphoe Umaporn; Engchanil Chulapan; Pancharoen Chitsanu; Lumbiganon Pagakrong; Intasan Jintana; Apateerapong Wichitra; Chuenyam Theshinee; Ubolyam Sasiwimol; Bunupuradah Torsak; Lange Joep; Cooper David A; Phanuphak Praphan;
A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection.
AIDS research and therapy 2008;5():24.
2007: Carey Dianne L; Baker David; Rogers Gary D; Petoumenos Kathy; Chuah John; Easey Nicole; Machon Kirsty; Cooper David A; Emery Sean; Carr Andrew;
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
Journal of acquired immune deficiency syndromes (1999) 2007;46(5):581-9.
2007: Emery S; Kelleher A D; Workman C; Puls R L; Bloch M; Baker D; Anderson J; Hoy J; Ip S; Nalliah K; Ward L D; Law M G; Cooper D A
Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.
Human vaccines 2007;3(6):260-7.
2007: Murray John M; Emery Sean; Kelleher Anthony D; Law Matthew; Chen Joshua; Hazuda Daria J; Nguyen Bach-Yen T; Teppler Hedy; Cooper David A
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
AIDS (London, England) 2007;21(17):2315-21.
2007: Wand Handan; Calmy Alexandra; Carey Dianne L; Samaras Katherine; Carr Andrew; Law Matthew G; Cooper David A; Emery Sean;
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
AIDS (London, England) 2007;21(18):2445-53.
2007: van Bockel David; Price David A; Asher Tedi E; Venturi Vanessa; Suzuki Kazuo; Warton Kristina; Davenport Miles P; Cooper David A; Douek Daniel C; Kelleher Anthony D
Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood.
Journal of immunological methods 2007;326(1-2):127-38.
2007: Poynten I M; Smith D E; Cooper D A; Kaldor J M; Grulich A E
The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV.
HIV medicine 2007;8(6):374-81.
2007: Reynes Jacques; Arastéh Keikawus; Clotet Bonaventura; Cohen Calvin; Cooper David A; Delfraissy Jean-François; Eron Joseph J; Henry Keith; Katlama Christine; Kuritzkes Daniel R; Lalezari Jacob P; Lange Joep; Lazzarin Adriano; Montaner Julio S G; Nelson Mark; O' Hearn Mary; Stellbrink Hans-Jürgen; Trottier Benoit; Walmsley Sharon L; Buss Neil E; Demasi Ralph; Chung Jain; Donatacci Lucille; Guimaraes Denise; Rowell Lucy; Valentine Adeline; Wilkinson Martin; Salgo Miklos P
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Dore Gregory J; Torriani Francesca J; Rodriguez-Torres Maribel; Bräu Norber; Sulkowski Mark; Lamoglia Ricard Sola; Tural Cristina; Clumeck Nathan; Nelson Mark R; Mendes-Correa Maria C; Godofsky Eliot W; Dieterich Douglas T; Yetzer Ellen; Lissen Eduardo; Cooper David A
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
AIDS (London, England) 2007;21(12):1555-9.
2007: Autar Reshma Saskia; Wit Ferdinand W N M; Sankote Jongkol; Sutthichom Duanghathai; Kimenai Elly; Hassink Elly; Hill Andrew; Cooper David A; Phanuphak Praphan; Lange Joep M A; Burger David M; Ruxrungtham Kiat
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
AIDS (London, England) 2007;21(12):1535-9.
2007: Boyd Mark A; Cooper David A
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research.
AIDS (London, England) 2007;21 Suppl 4():S55-63.
2007: Calmy Alexandra; Hirschel Bernard; Cooper David A; Carr Andrew
Clinical update: adverse effects of antiretroviral therapy.
Lancet 2007;370(9581):12-4.
2007: Nelson Mark R; Katlama Christine; Montaner Julio S; Cooper David A; Gazzard Brian; Clotet Bonaventura; Lazzarin Adriano; Schewe Knud; Lange Joep; Wyatt Christina; Curtis Sue; Chen Shan-Shan; Smith Stephen; Bischofberger Norbert; Rooney James F
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Winston Alan; Mallon Patrick W G; Satchell Claudette; MacRae Karen; Williams Kenneth M; Schutz Malte; Law Matthew; Cooper David A; Emery Sean
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(11):1475-83.
2007: Kerr Stephen J; Duncombe Chris; Avihingsanon Anchalee; Ananworanich Jintanat; Boyd Mark; Sopa Bunruan; Medtech B; Chuenyam Theshinee; Cooper David A; Lange Joep M A; Phanuphak Praphan; Ruxrungtham Kiat
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2007;6(1):36-46.
2007: Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd M A; Phanuphak P; Cooper D A; Law M G
Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
HIV medicine 2007;8(1):46-54.
2007: Zhou J; Paton N I; Ditangco R; Chen Y-M A; Kamarulzaman A; Kumarasamy N; Lee C K C; Li P C K; Merati T P; Phanuphak P; Pujari S; Vibhagool A; Zhang F; Chuah J; Frost K R; Cooper D A; Law M G
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
HIV medicine 2007;8(1):8-16.
2007: Dyer Wayne B; Pett Sarah L; Sullivan John S; Emery Sean; Cooper David A; Kelleher Anthony D; Lloyd Andrew; Lewin Sharon R
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.
Clinical and vaccine immunology : CVI 2007;14(1):52-9.
2007: Autar Reshma S; Boyd Mark A; Wit Ferdinand W M N; Ruxrungthams Kiat; Sankote Jongkol; Lange Joep; Cooper David A; Phanuphak Praphan; Burger David M; Reiss Peter
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Antiviral therapy 2007;12(8):1265-71.
2007: Matthews Gail V; Cooper David A; Dore Gregory J
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Antiviral therapy 2007;12(1):119-22.
2006: Gathe Joseph; Cooper David A; Farthing Charles; Jayaweera Dushyantha; Norris Dorece; Pierone Gerald; Steinhart Corklin R; Trottier Benoit; Walmsley Sharon L; Workman Cassy; Mukwaya Geoffrey; Kohlbrenner Veronika; Dohnanyi Catherine; McCallister Scott; Mayers Douglas;
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(10):1337-46.
2006: Boyd Mark A; Dixit Narendra M; Siangphoe Umaporn; Buss Neil E; Salgo Miklos P; Lange Joep M A; Phanuphak Praphan; Cooper David A; Perelson Alan S; Ruxrungtham Kiat
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
The Journal of infectious diseases 2006;194(9):1319-22.
2006: Zaunders John J; Ip Susanna; Munier Mee Ling; Kaufmann Daniel E; Suzuki Kazuo; Brereton Choechoe; Sasson Sarah C; Seddiki Nabila; Koelsch Kersten; Landay Alan; Grey Pat; Finlayson Robert; Kaldor John; Rosenberg Eric S; Walker Bruce D; Fazekas de St Groth Barbara; Cooper David A; Kelleher Anthony D
Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection.
Journal of virology 2006;80(20):10162-72.
2006: Zaunders John J; Dyer Wayne B; Munier Mee Ling; Ip Susanna; Liu Jie; Amyes Elisabeth; Rawlinson William; De Rose Robert; Kent Stephen J; Sullivan John S; Cooper David A; Kelleher Anthony D
CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells.
Journal of virology 2006;80(20):10151-61.
2006: Boyd Mark A; Carr Andrew; Ruxrungtham Kiat; Srasuebkul Preeyaporn; Bien Darl; Law Matthew; Wangsuphachart Somjai; Krisanachinda Anchali; Lerdlum Sakalaya; Lange Joep M A; Phanuphak Praphan; Cooper David A; Reiss Peter
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
The Journal of infectious diseases 2006;194(5):642-50.
2006: Hicks Charles B; Cahn Pedro; Cooper David A; Walmsley Sharon L; Katlama Christine; Clotet Bonaventura; Lazzarin Adriano; Johnson Margaret A; Neubacher Dietmar; Mayers Douglas; Valdez Hernan;
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Lancet 2006;368(9534):466-75.
2006: Dore Gregory J; Cooper David A
HAART's first decade: success brings further challenges.
Lancet 2006;368(9534):427-8.
2006: Yeni P; Cooper D A; Aboulker J P; Babiker A G; Carey D; Darbyshire J H; Floridia M; Girard P M; Goodall R L; Hooker M H; Mijch A; Meiffredy V; Salzberger B
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
Lancet 2006;368(9532):287-98.
2006: Bloch Mark T; Smith Don E; Quan Dick; Kaldor John M; Zaunders John J; Petoumenos Kathy; Irvine Kathy; Law Matthew; Grey Pat; Finlayson Robert J; McFarlane Robert; Kelleher Anthony D; Carr Andrew; Cooper David A
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
Journal of acquired immune deficiency syndromes (1999) 2006;42(2):192-202.
2006: Boyd Mark A; Siangphoe Umaporn; Ruxrungtham Kiat; Reiss Peter; Mahanontharit Apicha; Lange Joep M A; Phanuphak Praphan; Cooper David A; Burger David M
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
The Journal of antimicrobial chemotherapy 2006;57(6):1161-7.
2006: De Rose Robert; Sullivan Mark T; Dale C Jane; Kelleher Anthony D; Emery Sean; Cooper David A; Ramshaw Ian A; Boyle David B; Kent Stephen J
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials.
Human vaccines 2006;2(3):134-6.
2006: Boyd Mark A; Srasuebkul Preeyaporn; Ruxrungtham Kiat; Mackenzie Peter I; Uchaipichat Verawan; Stek Michael; Lange Joep M A; Phanuphak Praphan; Cooper David A; Udomuksorn Wandee; Miners John O
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
Pharmacogenetics and genomics 2006;16(5):321-9.
2006: Winston Alan; Amin Janaki; Hales Gill; Cooper David A; Emery Sean
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals.
AIDS research and human retroviruses 2006;22(4):338-41.
2006: Mallon Patrick W G; Miller John; Kovacic Jason C; Kent-Hughes Julia; Norris Richard; Samaras Katherine; Feneley Michael P; Cooper David A; Carr Andrew
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
AIDS (London, England) 2006;20(7):1003-10.
2006: Matthews Gail V; Bartholomeusz Angeline; Locarnini Stephen; Ayres Anna; Sasaduesz Joe; Seaberg Eric; Cooper David A; Lewin Sharon; Dore Gregory J; Thio Chloe L
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
AIDS (London, England) 2006;20(6):863-70.
2006: Winston A; Amin J; Mallon Pwg; Marriott D; Carr A; Cooper D A; Emery S
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
HIV medicine 2006;7(2):105-11.
2006: Hamlyn E; McAllister J; Winston A; Sinclair B; Amin J; Carr A; Cooper D A
Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?
Sexually transmitted infections 2006;82(1):21-3.
2006: Sasson Sarah C; Zaunders John J; Zanetti Giulia; King Eleanor M; Merlin Kate M; Smith Don E; Stanley Keith K; Cooper David A; Kelleher Anthony D
Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection.
The Journal of infectious diseases 2006;193(4):505-14.
2006: Kelleher Anthony D; Puls Rebekah L; Bebbington Mark; Boyle David; Ffrench Rosemary; Kent Stephen J; Kippax Sue; Purcell Damian F J; Thomson Scott; Wand Handan; Cooper David A; Emery Sean
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
AIDS (London, England) 2006;20(2):294-7.
2006: Boyd Mark A; Srasuebkul Preeyaporn; Khongphattanayothin Mana; Ruxrungtham Kiat; Hassink Elly A M; Duncombe Christopher J; Ubolyam Sasiwimol; Burger David M; Reiss Peter; Stek Michael; Lange Joep; Cooper David A; Phanuphak Praphan
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Antiviral therapy 2006;11(2):223-32.
2006: Law Matthew; Puls Rebekah; Cheng Andrew K; Cooper David A; Carr Andrew
Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults.
Antiviral therapy 2006;11(2):179-86.
2005: Nelson Mark; Arastéh Keikawus; Clotet Bonaventura; Cooper David A; Henry Keith; Katlama Christine; Lalezari Jacob P; Lazzarin Adriano; Montaner Julio S G; O'Hearn Mary; Piliero Peter J; Reynes Jacques; Trottier Benoit; Walmsley Sharon L; Cohen Calvin; Eron Joseph J; Kuritzkes Daniel R; Lange Joep; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Buss Neil E; Donatacci Lucille; Wat Cynthia; Smiley Lynn; Wilkinson Martin; Valentine Adeline; Guimaraes Denise; Demasi Ralph; Chung Jain; Salgo Miklos P
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Emery S; Workman C; Puls R L; Bloch M; Baker D; Bodsworth N; Anderson J; Crowe S M; French M A H; Hoy J; Aichelburg A; Ward L D; Boyle D B; Law M G; Kelleher A D; Cooper D A
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
Human vaccines 2005;1(6):232-8.
2005: Boyd M A; Siangphoe U; Ruxrungtham K; Duncombe C J; Stek M; Lange J M A; Cooper D A; Phanuphak P
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
HIV medicine 2005;6(6):410-20.
2005: Autar Reshma Saskia; Boffito Marta; Hassink Elly; Wit Ferdinand W N M; Ananworanich Jintanat; Siangphoe Umaporn; Pozniak Anton; Cooper David A; Phanuphak Praphan; Lange Joep M A; Ruxrungtham Kiat; Burger David M
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
The Journal of antimicrobial chemotherapy 2005;56(5):908-13.
2005: Winston Alan; Hales Gill; Amin Janaki; van Schaick Erno; Cooper David A; Emery Sean;
The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.
AIDS (London, England) 2005;19(13):1393-9.
2005: Zaunders John J; Munier Mee Ling; Kaufmann Daniel E; Ip Susanna; Grey Pat; Smith Don; Ramacciotti Tim; Quan Dick; Finlayson Robert; Kaldor John; Rosenberg Eric S; Walker Bruce D; Cooper David A; Kelleher Anthony D
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection.
Blood 2005;106(5):1660-7.
2005: Carey Dianne; Wand Handan; Martin Allison; Rothwell Sharyn; Emery Sean; Cooper David A; Carr Andrew;
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.
AIDS (London, England) 2005;19(12):1325-7.
2005: Sasson Sarah C; Kelleher Anthony D; Cooper David A
The modern ART of HIV infection management: towards a tailored approach to maximize CD4 T cell reconstitution.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(3):373-5.
2005: Winston Alan; Bloch Mark; Carr Andrew; Amin Janaki; Mallon Patrick W G; Ray John; Marriott Debbie; Cooper David A; Emery Sean
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
The Journal of antimicrobial chemotherapy 2005;56(2):380-7.
2005: Ammaranond Palanee; Zaunders John; Satchell Claudette; van Bockel David; Cooper David A; Kelleher Anthony D
A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1.
AIDS research and human retroviruses 2005;21(5):395-7.
2005: Mallon Patrick W G; Unemori Patrick; Sedwell Rebecca; Morey Adrienne; Rafferty Martina; Williams Kenneth; Chisholm Donald; Samaras Katherine; Emery Sean; Kelleher Anthony; Cooper David A; Carr Andrew;
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.
The Journal of infectious diseases 2005;191(10):1686-96.
2005: Cardiello Peter G; Hassink Elly; Ananworanich Jintanat; Srasuebkul Preeyaporn; Samor Tarika; Mahanontharit Apicha; Ruxrungtham Kiat; Hirschel Bernard; Lange Joep; Phanuphak Praphan; Cooper David A
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(4):594-600.
2005: Zhou Jialun; Kumarasamy N; Ditangco Rossana; Kamarulzaman Adeeba; Lee Christopher K C; Li Patrick C K; Paton Nicholas I; Phanuphak Praphan; Pujari Sanjay; Vibhagool Asda; Wong Wing-Wai; Zhang Fujie; Chuah John; Frost Kevin R; Cooper David A; Law Matthew G;
The TREAT Asia HIV Observational Database: baseline and retrospective data.
Journal of acquired immune deficiency syndromes (1999) 2005;38(2):174-9.
2005: Mallon Patrick W G; Wand Handan; Law Matthew; Miller John; Cooper David A; Carr Andrew;
Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.
Journal of acquired immune deficiency syndromes (1999) 2005;38(2):156-62.
2005: Ananworanich Jintanat; Moor Zewlan; Siangphoe Umaporn; Chan Jason; Cardiello Peter; Duncombe Chris; Phanuphak Praphan; Ruxrungtham Kiat; Lange Joep; Cooper David A
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
AIDS (London, England) 2005;19(2):185-92.
2005: Duncombe Chris; Kerr Stephen J; Ruxrungtham Kiat; Dore Gregory J; Law Matthew G; Emery Sean; Lange Joep M; Phanuphak Praphan; Cooper David A
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.
AIDS (London, England) 2005;19(2):169-78.
2005: Autar Reshma S; Wit Ferdinand W N M; Sankote Jongkol; Mahanontharit Apicha; Anekthananon Thanomsak; Mootsikapun Piroon; Sujaikaew Khanjtta; Cooper David A; Lange Joep M A; Phanuphak Praphan; Ruxrungtham Kiat; Burger David M
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Antiviral therapy 2005;10(8):937-43.
2005: Ananworanich Jintanat; Hill Andrew; Siangphoe Umaporn; Ruxrungtham Kiat; Prasithsirikul Wisit; Chetchotisakd Ploenchan; Kiertiburanakul Sasisopin; Munsakul Warangkana; Raksakulkarn Phitsanu; Tansuphasawadikul Somboon; Nuesch Reto; Cooper David A; Hirschel Bernard;
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Antiviral therapy 2005;10(6):761-7.
2005: Mallon Patrick W G; Sedwell Rebecca; Unemori Patrick; Kelleher Anthony; Cooper David A; Carr Andrew
Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy.
Antiviral therapy 2005;10 Suppl 2():M101-8.
2005: Kovacic Jason C; Martin Allison; Carey Dianne; Wand Handan; Mallon Patrick W G; Feneley Michael P; Emery Sean; Cooper David A; Carr Andrew;
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Antiviral therapy 2005;10(1):135-43.
2004: Vanhems Philippe; Voirin Nicolas; Philippe Pierre; Hirschel Bernard; Brassard Joelle; Carr Andrew; Cooper David A; Perrin Luc; Allard Robert;
The incubation period of acute retroviral syndrome as a multistep process: a parametric survival analysis.
Journal of acquired immune deficiency syndromes (1999) 2004;37(4):1529-33.
2004: Dale C Jane; De Rose Robert; Wilson Kim M; Croom Hayley A; Thomson Scott; Coupar Barbara E H; Ramsay Alistair; Purcell Damian F J; Ffrench Rosemary; Law Matthew; Emery Sean; Cooper David A; Ramshaw Ian A; Boyle David B; Kent Stephen J;
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12.
Vaccine 2004;23(2):188-97.
2004: Safreed-Harmon Kelly; Cooper David A; Lange Joep M A; Duncombe Chris; Phanuphak Praphan
The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research.
AIDS (London, England) 2004;18(15):1971-8.
2004: Martin Allison; Smith Don; Carr Andrew; Hoy Jennifer; Chuah John; Mallal Simon; Law Matthew; Clements Mark; Cooper David A;
Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
HIV clinical trials 2004;5(4):192-200.
2004: Cooper David A; Lange Joep M A
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
The Lancet infectious diseases 2004;4(7):426-36.
2004: Ungsedhapand Chaiwat; Srasuebkul Preeyaporn; Cardiello Peter; Ruxrungtham Kiat; Ratanasuwan Winai; Kroon Eugene D M B; Tongtalung Metta; Juengprasert Nittaya; Ubolyam Sasiwimol; Siangphoe Umaporn; Emery Sean; Lange Joep M A; Cooper David A; Phanuphak Praphan;
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):693-701.
2004: Law W Phillip; Duncombe Chris J; Mahanontharit Apicha; Boyd Mark A; Ruxrungtham Kiat; Lange Joep M A; Phanuphak Praphan; Cooper David A; Dore Gregory J
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
AIDS (London, England) 2004;18(8):1169-77.
2004: Amin J; Kaye M; Skidmore S; Pillay D; Cooper D A; Dore G J
HIV and hepatitis C coinfection within the CAESAR study.
HIV medicine 2004;5(3):174-9.
2004: Martin Allison; Smith Don E; Carr Andrew; Ringland Clare; Amin Janaki; Emery Sean; Hoy Jennifer; Workman Cassy; Doong Nicholas; Freund Judith; Cooper David A;
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
AIDS (London, England) 2004;18(7):1029-36.
2004: Dore Gregory J; Cooper David A; Pozniak Anton L; DeJesus Edwin; Zhong Lijie; Miller Michael D; Lu Biao; Cheng Andrew K;
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
The Journal of infectious diseases 2004;189(7):1185-92.
2004: Zaunders John J; Dyer Wayne B; Wang Bin; Munier Mee Ling; Miranda-Saksena Monica; Newton Rebecca; Moore John; Mackay Charles R; Cooper David A; Saksena Nitin K; Kelleher Anthony D
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection.
Blood 2004;103(6):2238-47.
2004: Carr Andrew; Workman Cassy; Carey Dianne; Rogers Gary; Martin Allison; Baker David; Wand Handan; Law Matthew; Samaras Katherine; Emery Sean; Cooper David A;
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Lancet 2004;363(9407):429-38.
2003: Keoshkerian Elizabeth; Ashton Lesley J; Smith Danielle G; Ziegler John B; Kaldor John M; Cooper David A; Stewart Graeme J; Ffrench Rosemary A
Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.
Journal of medical virology 2003;71(4):483-91.
2003: Boyd Mark A; Aarnoutse Rob E; Ruxrungtham Kiat; Stek Michael; van Heeswijk Rolf P G; Lange Joep M A; Cooper David A; Phanuphak Praphan; Burger David M
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):134-9.
2003: Law W Phillip; Dore Gregory J; Duncombe Chris J; Mahanontharit Apicha; Boyd Mark A; Ruxrungtham Kiat; Lange Joep M A; Phanuphak Praphan; Cooper David A
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
AIDS (London, England) 2003;17(15):2191-9.
2003: Amin J; Moore A; Carr A; French M A; Law M; Emery S; Cooper D A;
Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
HIV clinical trials 2003;4(4):252-61.
2003: Miller J; Carr A; Emery S; Law M; Mallal S; Baker D; Smith D; Kaldor J; Cooper D A
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.
HIV medicine 2003;4(3):293-301.
2003: Cardiello Peter G; Samor Tarika; Burger David; Hoetelmans Richard; Mahanontharit Apicha; Ruxrungtham Kiat; Lange Joep M; Cooper David A; Phanuphak Praphan
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.
Antiviral therapy 2003;8(3):245-9.
2003: Zaunders John J; Moutouh-de Parseval Laure; Kitada Shinichi; Reed John C; Rought Steffney; Genini Davide; Leoni Lorenzo; Kelleher Anthony; Cooper David A; Smith Don E; Grey Pat; Estaquier Jérôme; Little Susan; Richman Douglas D; Corbeil Jacques
Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2.
The Journal of infectious diseases 2003;187(11):1735-47.
2003: Mallon Patrick W; Miller John; Cooper David A; Carr Andrew
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
AIDS (London, England) 2003;17(7):971-9.
2003: Vanhems Philippe; Voirin Nicolas; Hirschel Bernard; Cooper David A; Vizzard Jeanette; Carr Andrew; Perrin Luc;
Brief report: incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS.
Journal of acquired immune deficiency syndromes (1999) 2003;32(5):542-4.
2003: Cardiello Peter G; Monhaphol Tarkika; Mahanontharit Apicha; van Heeswijk Rolf P; Burger David; Hill Andrew; Ruxrungtham Kiat; Lange Joep M; Cooper David A; Phanuphak Praphan
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):375-9.
2003: Smith Don E; Kaufmann Gilbert R; Kahn James O; Hecht Frederick M; Grey Patricia A; Zaunders John J; Cunningham Philip H; Carr Andrew; Duncombe Christopher; Quan Dick C; Petersen Annkatrin; Cooper David A
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.
AIDS research and human retroviruses 2003;19(3):189-99.
2003: Mallon Patrick W G; Ray John; Cooper David A
Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;26(2):223-7.
2003: Ammaranond Palanee; Cunningham Philip; Oelrichs Robert; Suzuki Kazuo; Harris Claire; Leas Leakhena; Grulich Andrew; Cooper David A; Kelleher Anthony D
Rates of transmission of antiretroviral drug resistant strains of HIV-1.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;26(2):153-61.
2003: Smith Don E; Hudson Jeff; Martin Allison; Freund Judith; Griffiths Matthew R; Kalnins Sue; Law Matthew; Carr Andrew; Cooper David A;
Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy.
HIV clinical trials 2003;4(1):45-9.
2003: Ammaranond Palanee; Cunningham Philip; Oelrichs Robert; Suzuki Kazuo; Harris Claire; Leas Leakhena; Grulich Andrew; Cooper David A; Kelleher Anthony D
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001.
AIDS (London, England) 2003;17(2):264-7.
2002: Wang Bin; Dyer Wayne B; Zaunders John J; Mikhail Meriet; Sullivan John S; Williams Lisa; Haddad Da'ed N; Harris Graeme; Holt John A G; Cooper David A; Miranda-Saksena Monica; Boadle Ross; Kelleher Anthony D; Saksena Nitin K
Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection.
Virology 2002;304(2):246-64.
2002: Smith Don E; Carr Andrew; Law Matthew; Martin Allison; Hudson Jeff; Hoy Jennifer; Cooper David A
Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study.
AIDS (London, England) 2002;16(18):2489-91.
2002: Pett Sarah L; Dore Greg J; Fielden Robert J; Cooper David A
Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1.
AIDS (London, England) 2002;16(17):2364-5.
2002: Vanhems Philippe; Routy Jean-Pierre; Hirschel Bernard; Baratin Dominique; Vora Samir; Maenza Janine; Carr Andrew; Trépo Christian; Touraine Jean-Louis; Gillibert René-Pierre; Collier Ann C; Cooper David A; Vizzard Jeanette; Sékaly Rafick-Pierre; Fabry Jacques; Perrin Luc;
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age.
Journal of acquired immune deficiency syndromes (1999) 2002;31(3):318-21.
2002: Vanhems Philippe; Caillat-Vallet Emmanuelle; Hirschel Bernard; Routy Jean-Pierre; Carr Andrew; Vizzard Jeanette; Cooper David A; Perrin Luc;
The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual.
AIDS (London, England) 2002;16(16):2234-6.
2002: Carr Andrew; Workman Cassy; Smith Don E; Hoy Jennifer; Hudson Jeff; Doong Nicholas; Martin Allison; Amin Janaki; Freund Judith; Law Matthew; Cooper David A;
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
JAMA : the journal of the American Medical Association 2002;288(2):207-15.
2002: Appay Victor; Zaunders John J; Papagno Laura; Sutton Julian; Jaramillo Angel; Waters Anele; Easterbrook Philippa; Grey Pat; Smith Don; McMichael Andrew J; Cooper David A; Rowland-Jones Sarah L; Kelleher Anthony D
Characterization of CD4(+) CTLs ex vivo.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(11):5954-8.
2002: Mallon Patrick W G; Carr Andrew; Cooper David A
HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.
Current diabetes reports 2002;2(2):116-24.
2002: Ashton L J; Stewart G J; Biti R; Law M; Cooper D A; Kaldor J M
Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens.
HIV medicine 2002;3(2):91-6.
2002: Cardiello Peter G; van Heeswijk Rolf P; Hassink Elly A; Srasuebkul Preeyaporn; Mahanontharit Apicha; Samor Tarika M; Worarien Wassana; Beijnen Jos H; Hoetelmans Richard M; Ruxrungtham Kiat; Cooper David A; Lange Joep M; Phanuphak Praphan
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Rongkavilit Chokechai; van Heeswijk Rolf P G; Limpongsanurak Sompop; Thaithumyanon Pimolrat; Boonrod Chantana; Hassink Elly A M; Srigritsanapol Aeumporn; Chuenyam Theshinee; Ubolyam Sasiwimol; Hoetelmans Richard M W; Ruxrungtham Kiat; Lange Joep M A; Cooper David A; Phanuphak Praphan
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):455-63.
2002: Emery Sean; Abrams Donald I; Cooper David A; Darbyshire Janet H; Lane H Clifford; Lundgren Jens D; Neaton James D;
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.
Controlled clinical trials 2002;23(2):198-220.
2002: Kaufmann Gilbert R; Bloch Mark; Finlayson Robert; Zaunders John; Smith Don; Cooper David A
The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
AIDS (London, England) 2002;16(3):359-67.
2002: Wilkinson J; Zaunders J J; Carr A; Guillemin G; Cooper D A
Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti-HIV-1 suppressor activity (CASA).
Clinical and experimental immunology 2002;127(1):145-50.
2002: Emery Sean; Cooper David A
HIV medicine.
The Medical journal of Australia 2002;176(1):21.
2002: Cooper David A
Update on didanosine.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2002;1(1):15-25.
2001: Dore G J; Cooper D A
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Current opinion in infectious diseases 2001;14(6):749-55.
2001: Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle B D; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink E A; Hoetelmans R M; Cooper D A; Lange J M; Ruxrungtham K; Phanuphak P
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Antimicrobial agents and chemotherapy 2001;45(12):3585-90.
2001: Smith D; Gow I; Colebunders R; Weller I; Tchamouroff S; Weber J; Boag F; Hales G; Adams S; Patou G; Cooper D A;
Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.
HIV medicine 2001;2(4):272-5.
2001: Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper D A;
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
AIDS (London, England) 2001;15(14):1811-22.
2001: Suzuki K; Kaufmann G R; Mukaide M; Cunningham P; Harris C; Leas L; Kondo M; Imai M; Pett S L; Finlayson R; Zaunders J; Kelleher A; Cooper D A
Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
AIDS research and human retroviruses 2001;17(13):1293-6.
2001: Mallon P W; Cooper D A; Carr A
HIV-associated lipodystrophy.
HIV medicine 2001;2(3):166-73.
2001: Ungsedhapand C; Kroon E D; Suwanagool S; Ruxrungtham K; Yimsuan N; Sonjai A; Ubolyam S; Buranapraditkun S; Tiengrim S; Pakker N; Kunanusont C; Lange J M; Cooper D A; Phanuphak P
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Journal of acquired immune deficiency syndromes (1999) 2001;27(2):116-23.
2001: Carr A; Miller J; Eisman J A; Cooper D A
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
AIDS (London, England) 2001;15(6):703-9.
2001: Kaufmann G R; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper D A
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
AIDS research and human retroviruses 2001;17(6):487-97.
2001: Zaunders J J; Kaufmann G R; Cunningham P H; Smith D; Grey P; Suzuki K; Carr A; Goh L E; Cooper D A
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 2001;183(5):736-43.
2001: Kaufmann G R; Zaunders J; Murray J; Kelleher A D; Lewin S R; Solomon A; Smith D; Cooper D A
Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling.
AIDS research and human retroviruses 2001;17(2):147-59.
2000: Kaufmann G R; Zaunders J J; Cunningham P; Kelleher A D; Grey P; Smith D; Carr A; Cooper D A
Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.
AIDS (London, England) 2000;14(17):2643-51.
2000: Miller J; Carr A; Smith D; Emery S; Law M G; Grey P; Cooper D A
Lipodystrophy following antiretroviral therapy of primary HIV infection.
AIDS (London, England) 2000;14(15):2406-7.
2000: Carr A; Cooper D A
Adverse effects of antiretroviral therapy.
Lancet 2000;356(9239):1423-30.
2000: Cunningham P H; Smith D G; Satchell C; Cooper D A; Brew B
Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
AIDS (London, England) 2000;14(13):1949-54.
2000: Smith D; Berrey M M; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper D A
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 2000;182(3):950-4.
2000: Emery S; Capra W B; Cooper D A; Mitsuyasu R T; Kovacs J A; Vig P; Smolskis M; Saravolatz L D; Lane H C; Fyfe G A; Curtin P T
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.
The Journal of infectious diseases 2000;182(2):428-34.
2000: Ruxrungtham K; Kroon E D; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling G J; Kunanusont C; Lange J M; Cooper D A; Phanuphak P
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
AIDS (London, England) 2000;14(10):1375-82.
2000: Kroon E D; Ungsedhapand C; Ruxrungtham K; Chuenyam M; Ubolyam S; Newell M E; van Leeuwen R; Kunanusont C; Buranapraditkul S; Sirivichayakul S; Lange J M; Cooper D A; Phanuphak P
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
AIDS (London, England) 2000;14(10):1349-56.
2000: Vanhems P; Hirschel B; Phillips A N; Cooper D A; Vizzard J; Brassard J; Perrin L
Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS.
The Journal of infectious diseases 2000;182(1):334-7.
2000: Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper D A
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
AIDS (London, England) 2000;14(9):1171-80.
2000: Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper D A; Yerly S
Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
AIDS (London, England) 2000;14(8):1065-7.
2000: Kaufmann G R; Bloch M; Zaunders J J; Smith D; Cooper D A
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
AIDS (London, England) 2000;14(8):959-69.
2000: Vanhems P; Hughes J; Collier A C; Vizzard J; Perrin L; Cooper D A; Hirschel B; Corey L
Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney.
AIDS (London, England) 2000;14(4):375-81.
2000: Carr A; Miller J; Law M; Cooper D A
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
AIDS (London, England) 2000;14(3):F25-32.
2000: Law M G; Li Y; McDonald A M; Cooper D A; Kaldor J M
Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection.
AIDS (London, England) 2000;14(2):197-201.
2000: Grulich A E; Wan X; Law M G; Milliken S T; Lewis C R; Garsia R J; Gold J; Finlayson R J; Cooper D A; Kaldor J M
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS.
AIDS (London, England) 2000;14(2):133-40.
1999: Kaufmann G R; Cunningham P; Zaunders J; Law M; Vizzard J; Carr A; Cooper D A
Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group.
Journal of acquired immune deficiency syndromes (1999) 1999;22(5):437-44.
1999: Zaunders J J; Geczy A F; Dyer W B; McIntyre L B; Cooley M A; Ashton L J; Raynes-Greenow C H; Learmont J; Cooper D A; Sullivan J S
Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes.
AIDS research and human retroviruses 1999;15(17):1519-27.
1999: Dore G J; Cooper D A; Barrett C; Goh L E; Thakrar B; Atkins M
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
The Journal of infectious diseases 1999;180(3):607-13.
1999: Kaufmann G R; Zaunders J; Cooper D A
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.
Sexually transmitted infections 1999;75(4):218-24.
1999: Zaunders J J; Cunningham P H; Kelleher A D; Kaufmann G R; Jaramillo A B; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper D A
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
The Journal of infectious diseases 1999;180(2):320-9.
1999: Kaufmann G R; Zaunders J J; Cunningham P; Cooper D A
Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
AIDS research and human retroviruses 1999;15(11):963-72.
1999: Dore G J; Correll P K; Li Y; Kaldor J M; Cooper D A; Brew B J
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.
AIDS (London, England) 1999;13(10):1249-53.
1999: Wilkinson J; Zaunders J J; Carr A; Cooper D A
CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.
The Journal of infectious diseases 1999;180(1):68-75.
1999: Vanhems P; Dassa C; Lambert J; Cooper D A; Perrin L; Vizzard J; Hirschel B; Kinloch-de Loës S; Carr A; Allard R
Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 1999;21(2):99-106.
1999: Grulich A E; Olsen S J; Luo K; Hendry O; Cunningham P; Cooper D A; Gao S J; Chang Y; Moore P S; Kaldor J M
Kaposi's sarcoma-associated herpesvirus: a sexually transmissible infection?
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999;20(4):387-93.
1999: Easterbrook P J; Goodall R L; Babiker A G; Yu L M; Smith D; Cooper D A; Gazzard B G
Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?
The Journal of antimicrobial chemotherapy 1999;43(3):379-88.
1999: Law M G; de Winter L; McDonald A; Cooper D A; Kaldor J M
AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment.
AIDS (London, England) 1999;13(2):263-9.
1999: Benson E M; Clarkson J; Law M; Marshall P; Kelleher A D; Smith D E; Patou G; Stewart G J; Cooper D A; French R A
Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
AIDS research and human retroviruses 1999;15(2):105-13.
1998: Newell M; Milliken S; Goldstein D; Lewis C; Boyle M; Dolan G; Ryan S; Cooper D A
A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.
Australian and New Zealand journal of medicine 1998;28(6):777-83.
1998: Murray J M; Kaufmann G; Kelleher A D; Cooper D A
A model of primary HIV-1 infection.
Mathematical biosciences 1998;154(2):57-85.
1998: Carr A; Cooper D A
HIV and AIDS. Gap between biology and reality in AIDS.
Lancet 1998;352 Suppl 4():SIV16.
1998: Kaufmann G R; Cunningham P; Kelleher A D; Zaunders J; Carr A; Vizzard J; Law M; Cooper D A
Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases 1998;178(6):1812-5.
1998: Correll P K; Law M G; McDonald A M; Cooper D A; Kaldor J M
HIV disease progression in Australia in the time of combination antiretroviral therapies.
The Medical journal of Australia 1998;169(9):469-72.
1998: Carr A; Emery S; Lloyd A; Hoy J; Garsia R; French M; Stewart G; Fyfe G; Cooper D A
Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.
The Journal of infectious diseases 1998;178(4):992-9.
1998: Carr A; Cooper D A
Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor.
The New England journal of medicine 1998;339(18):1296.
1998: Kaufmann G R; Duncombe C; Cunningham P; Beveridge A; Carr A; Sayer D; French M; Cooper D A
Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
AIDS (London, England) 1998;12(13):1625-30.
1998: Goldstein D; Hertzog P; Tomkinson E; Couldwell D; McCarville S; Parrish S; Cunningham P; Newell M; Owens M; Cooper D A
Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification.
The Journal of infectious diseases 1998;178(3):858-61.
1998: Kelleher A D; Roggensack M; Emery S; Carr A; French M A; Cooper D A
Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.
Clinical and experimental immunology 1998;113(1):85-91.
1998: Carr A; Samaras K; Chisholm D J; Cooper D A
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Lancet 1998;351(9119):1881-3.
1998: Vanhems P; Lambert J; Cooper D A; Perrin L; Carr A; Hirschel B; Vizzard J; Kinloch-de Loës S; Allard R
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(2):323-9.
1998: Kelleher A D; Roggensack M; Jaramillo A B; Smith D E; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper D A
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
AIDS (London, England) 1998;12(2):175-82.
1998: Ashton L J; Carr A; Cunningham P H; Roggensack M; McLean K; Law M; Robertson M; Cooper D A; Kaldor J M
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group.
AIDS research and human retroviruses 1998;14(2):117-21.
1998: Cooper D A
Immunological effects of antiretroviral therapy.
Antiviral therapy 1998;3 Suppl 4():19-23.
1998: Phanuphak P; Cooper D A; Lange J M
Clinical trials in Asia.
AIDS (London, England) 1998;12 Suppl B():S163-7.
1997: Stewart G J; Ashton L J; Biti R A; Ffrench R A; Bennetts B H; Newcombe N R; Benson E M; Carr A; Cooper D A; Kaldor J M
Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
AIDS (London, England) 1997;11(15):1833-8.
1997: McNulty A; Law M G; Bodsworth N J; Cooper D A; Kaldor J M
Incidence of HIV infection in a cohort of homosexually active men.
Australian and New Zealand journal of public health 1997;21(6):587-9.
1997: Dore G J; Hoy J F; Mallal S A; Li Y; Mijch A M; French M A; Cooper D A; Kaldor J M
Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(1):39-43.
1997: Imrie A; Beveridge A; Genn W; Vizzard J; Cooper D A
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases 1997;175(6):1502-6.
1997: Vanhems P; Allard R; Cooper D A; Perrin L; Vizzard J; Hirschel B; Kinloch-de Löes S; Carr A; Lambert J
Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(5):965-70.
1997: Grulich A E; Kaldor J M; Hendry O; Luo K; Bodsworth N J; Cooper D A
Risk of Kaposi's sarcoma and oroanal sexual contact.
American journal of epidemiology 1997;145(8):673-9.
1997: Thackway S V; Furner V; Mijch A; Cooper D A; Holland D; Martinez P; Shaw D; van Beek I; Wright E; Clezy K; Kaldor J M
Fertility and reproductive choice in women with HIV-1 infection.
AIDS (London, England) 1997;11(5):663-7.
1997: de Jong M D; Vella S; Carr A; Boucher C A; Imrie A; French M; Hoy J; Sorice S; Pauluzzi S; Chiodo F; Weverling G J; van der Ende M E; Frissen P J; Weigel H M; Kauffmann R H; Lange J M; Yoon R; Moroni M; Hoenderdos E; Leitz G; Cooper D A; Hall D; Reiss P
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1997: Kelleher A D; Emery S; Cunningham P; Duncombe C; Carr A; Golding H; Forde S; Hudson J; Roggensack M; Forrest B D; Cooper D A
Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.
AIDS research and human retroviruses 1997;13(1):29-32.
1996: Zheng N N; Hurren L; Neilan B A; Cooper D A; Delaney S F; McQueen P W
Sequence analyses of the reverse transcriptase region of HIV type 1 isolates from Sydney, Australia.
AIDS research and human retroviruses 1996;12(18):1731-2.
1996: Carr A; Emery S; Kelleher A; Law M; Cooper D A
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;13(4):320-6.
1996: Dore G J; Li Y; Grulich A E; Hoy J F; Mallal S A; Mijch A M; French M A; Cooper D A; Kaldor J M
Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort.
AIDS (London, England) 1996;10(12):1401-6.
1996: Cooper D A
The ascendancy--and the future--of combination antiretroviral and immunomodulatory therapies.
Journal of the International Association of Physicians in AIDS Care 1996;2(8):20-5.
1996: Imrie A; Carr A; Duncombe C; Finlayson R; Vizzard J; Law M; Kaldor J; Penny R; Cooper D A
Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases 1996;174(1):195-8.
1996: Cramp M E; Hing M C; Marriott D J; Freund J; Cooper D A
Bile acid malabsorption in HIV infected patients with chronic diarrhoea.
Australian and New Zealand journal of medicine 1996;26(3):368-71.
1996: Carr A; Vella S; de Jong M D; Sorice F; Imrie A; Boucher C A; Cooper D A
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
AIDS (London, England) 1996;10(6):635-41.
1996: Couldwell D L; Dore G J; Harkness J L; Marriott D J; Cooper D A; Edwards R; Li Y; Kaldor J M
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room.
AIDS (London, England) 1996;10(5):521-5.
1996: Zheng N N; McQueen P W; Hurren L; Evans L A; Law M G; Forde S; Barker S; Cooper D A; Delaney S F
Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine.
The Journal of infectious diseases 1996;173(5):1092-6.
1996: Cooper D A
An interview with David A. Cooper, MD, DSc. Interview by Mark Mascolini.
Journal of the International Association of Physicians in AIDS Care 1996;2(3):17-22.
1996: Cooper D A
Australia's healthcare system.
Journal of the International Association of Physicians in AIDS Care 1996;2(3):14-6.
1996: Kelleher A D; Carr A; Zaunders J; Cooper D A
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
The Journal of infectious diseases 1996;173(2):321-9.
1996: Cooper D A; Merigan T C
Clinical treatment.
AIDS (London, England) 1996;10 Suppl A():S133-4.
1996: Carr A; Cooper D A
Current clinical experience with nevirapine for HIV infection.
Advances in experimental medicine and biology 1996;394():299-304.
1995: Distler O; McQueen P W; Tsang M L; Evans L A; Hurren L; Byrne C; Penny R; Cooper D A; Delaney S F
Primary structure of the V3 region of gp120 from sequential human immunodeficiency virus type 1 isolates obtained from patients from the time of seroconversion.
The Journal of infectious diseases 1995;172(5):1384-7.
1995: Emery S; Cooper D A
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
Australian and New Zealand journal of medicine 1995;25(4):344-9.
1995: Zaunders J; Carr A; McNally L; Penny R; Cooper D A
Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes.
AIDS (London, England) 1995;9(6):561-6.
1995: McNulty A M; Kaldor J M; Cooper D A
Change in zidovudine prescribing practices in Australia, 1991-1993.
Australian and New Zealand journal of medicine 1995;25(3):239-40.
1995: Corbeil J; Evans L A; McQueen P W; Vasak E; Edward P D; Richman D D; Penny R; Cooper D A
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1.
Immunology and cell biology 1995;73(2):140-5.
1995: Distler O; McQueen P W; Tsang M L; Byrne C; Neilan B A; Evans L; Penny R; Cooper D A; Delaney S F
Characterization of the V3 region of HIV-1 isolates from Sydney, Australia.
AIDS research and human retroviruses 1995;11(3):423-5.
1995: Luo K; Law M; Kaldor J M; McDonald A M; Cooper D A
The role of initial AIDS-defining illness in survival following AIDS.
AIDS (London, England) 1995;9(1):57-63.
1995: Carr A; Cooper D A
Pathogenesis and management of HIV-associated drug hypersensitivity.
AIDS clinical review 1995;():65-97.
1994: Grunseit A C; Perdices M; Dunbar N; Cooper D A
Neuropsychological function in asymptomatic HIV-1 infection: methodological issues.
Journal of clinical and experimental neuropsychology 1994;16(6):898-910.
1994: Tindall B; Forde S; Ross M W; Goldstein D; Barker S; Cooper D A
Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine.
Patient education and counseling 1994;24(3):261-6.
1994: Tsang M L; Evans L A; McQueen P; Hurren L; Byrne C; Penny R; Tindall B; Cooper D A
Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
The Journal of infectious diseases 1994;170(5):1141-7.
1994: Cooper D A
HIV therapy advances. Early antiretroviral therapy.
AIDS (London, England) 1994;8 Suppl 3():S9-14.
1994: Carr A; Vasak E; Munro V; Penny R; Cooper D A
Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection.
Clinical and experimental immunology 1994;97(2):260-5.
1994: Swanson C E; Tindall B; Cooper D A
Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.
AIDS (London, England) 1994;8(5):625-34.
1994: Carr A; Gross A S; Hoskins J M; Penny R; Cooper D A
Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.
AIDS (London, England) 1994;8(3):333-7.
1994: Tindall B; Forde S; Goldstein D; Ross M W; Cooper D A
Sexual dysfunction in advanced HIV disease.
AIDS care 1994;6(1):105-7.
1994: Clezy K; Sirisanthana T; Sirisanthana V; Brew B; Cooper D A
Late manifestations of HIV in Asia and the Pacific.
AIDS (London, England) 1994;8 Suppl 2():S35-43.
1993: Carr A; Tindall B; Penny R; Cooper D A
In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV.
Clinical and experimental immunology 1993;94(1):21-5.
1993: Kaldor J M; Tindall B; Williamson P; Elford J; Cooper D A
Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men.
Journal of acquired immune deficiency syndromes 1993;6(10):1145-9.
1993: Carr A; Loewenthal M; Cooper D A
Update on reverse transcriptase inhibitors in HIV disease.
Israel journal of medical sciences 1993;29(10 Suppl):26-30.
1993: Tindall B; Forde S; Carr A; Barker S; Cooper D A
Attitudes to euthanasia and assisted suicide in a group of homosexual men with advanced HIV disease.
Journal of acquired immune deficiency syndromes 1993;6(9):1069-70.
1993: Tindall B; Elford J; Sharkey T; Carr A; Kaldor J; Cooper D A
CD4+ lymphocytopenia in HIV-seronegative homosexual men.
AIDS (London, England) 1993;7(9):1272-3.
1993: Cooper D A; Gatell J M; Kroon S; Clumeck N; Millard J; Goebel F D; Bruun J N; Stingl G; Melville R L; González-Lahoz J
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
The New England journal of medicine 1993;329(5):297-303.
1993: Bell S J; Geczy A F; Russell-Jones G J; Croft S; Cooper D A; Penny R
Augmentation of HIV-specific lymphoproliferation in HIV-infected individuals by TraT: a novel T-cell immunopotentiating agent.
AIDS (London, England) 1993;7(6):807-12.
1993: Boyle M J; Sculley T B; Penny R; Sewell W A; Tschuchnigg M; Berger M F; Cooper D A
The role of Epstein-Barr virus subtypes in human immunodeficiency virus-associated lymphoma.
Leukemia & lymphoma 1993;10(1-2):17-23.
1993: Boyle M J; Berger M F; Tschuchnigg M; Valentine J E; Kennedy B G; Divjak M; Cooper D A; Turner J J; Penny R; Sewell W A
Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients.
Clinical and experimental immunology 1993;92(1):100-5.
1993: Carr A; Penny R; Cooper D A
Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS).
The Journal of allergy and clinical immunology 1993;91(2):683-5.
1993: Cooper D A; Pehrson P O; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
AIDS (London, England) 1993;7(2):197-207.
1993: Carr A; Penny R; Cooper D A
Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.
AIDS (London, England) 1993;7(1):65-71.
1993: Boyle M J; McMurchie M; Tindall B; Cooper D A
HIV seroconversion illness.
The Medical journal of Australia 1993;158(1):42-4.
1993: Boyle M J; Vasak E; Tschuchnigg M; Turner J J; Sculley T; Penny R; Cooper D A; Tindall B; Sewell W A
Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise.
Blood 1993;81(2):468-74.
1993: Carr A; Swanson C; Penny R; Cooper D A
Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS.
The Journal of infectious diseases 1993;167(1):180-5.
1993: Goldstein D; Cooper D A
Current status of clinical trials in HIV disease in Australia.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S68-71.
1993: Carr A; Penny R; Cooper D A
Prophylaxis of opportunistic infections in patients with HIV infection.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S56-60.
1993: Boyle M J; Sewell W A; Milliken S T; Cooper D A; Penny R
HIV and malignancy.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S5-9.
1992: Perdices M; Dunbar N; Grunseit A; Hall W; Cooper D A
Anxiety, depression and HIV related symptomatology across the spectrum of HIV disease.
The Australian and New Zealand journal of psychiatry 1992;26(4):560-6.
1992: Kyaw M T; Hurren L; Evans L; Moss D J; Cooper D A; Benson E; Esmore D; Sculley T B
Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients.
AIDS research and human retroviruses 1992;8(11):1869-74.
1992: Bell S J; Cooper D A; Kemp B E; Doherty R R; Penny R
Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI).
Clinical and experimental immunology 1992;90(1):6-12.
1992: Learmont J; Tindall B; Evans L; Cunningham A; Cunningham P; Wells J; Penny R; Kaldor J; Cooper D A
Long-term symptomless HIV-1 infection in recipients of blood products from a single donor.
Lancet 1992;340(8824):863-7.
1992: Bell S J; Cooper D A; Kemp B E; Doherty R R; Penny R
CD8+ T-cells from HIV-infected patients can either augment or abrogate HIV-specific lymphoproliferation.
Clinical immunology and immunopathology 1992;64(3):254-60.
1992: Tindall B; Evans L; Cunningham P; McQueen P; Hurren L; Vasak E; Mooney J; Cooper D A
Identification of HIV-1 in semen following primary HIV-1 infection.
AIDS (London, England) 1992;6(9):949-52.
1992: Tindall B; Sharkey T; Kaldor J; Cooper D A
Effect of the revised CDC case definition of AIDS on the number of AIDS cases in the Sydney AIDS Prospective Study.
Australian and New Zealand journal of medicine 1992;22(4):369-73.
1992: Dunbar N; Perdices M; Grunseit A; Cooper D A
Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS.
AIDS (London, England) 1992;6(7):691-700.
1992: Carr A; Tindall B; Brew B J; Marriott D J; Harkness J L; Penny R; Cooper D A
Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.
Annals of internal medicine 1992;117(2):106-11.
1992: Boyle M J; Sculley T B; Cooper D A; Turner J J; Penny R; Sewell W A
Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome.
Clinical and experimental immunology 1992;87(3):357-61.
1992: Carr A; Tindall B; Penny R; Cooper D A
Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
AIDS (London, England) 1992;6(2):165-71.
1992: Bell S J; Cooper D A; Kemp B E; Doherty R R; Penny R
Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1.
Clinical and experimental immunology 1992;87(1):37-45.
1991: Boyle M J; Sewell W A; Sculley T B; Apolloni A; Turner J J; Swanson C E; Penny R; Cooper D A
Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.
Blood 1991;78(11):3004-11.
1991: Cooper D A; Pedersen C; Aiuti F; Vilde J L; Ruhnke M; Pehrson P O; Clumeck N; Farthing C; Lüthy R; Doherty R R
The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group.
AIDS (London, England) 1991;5(8):933-43.
1991: Corbeil J; Evans L A; Vasak E; Cooper D A; Penny R
Culture and properties of cells derived from Kaposi sarcoma.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(9):2972-6.
1991: Tindall B; Gaines H; Imrie A; von Sydow M A; Evans L; Strannegard O; Tsang M L; Lindback S; Cooper D A
Zidovudine in the management of primary HIV-1 infection.
AIDS (London, England) 1991;5(5):477-84.
1991: Tenant-Flowers M; Boyle M J; Carey D; Marriott D J; Harkness J L; Penny R; Cooper D A
Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis.
AIDS (London, England) 1991;5(3):311-5.
1991: Carr A; Cooper D A; Penny R
Allergic manifestations of human immunodeficiency virus (HIV) infection.
Journal of clinical immunology 1991;11(2):55-64.
1991: Lange J M; Cooper D A; Danner S A
Antiretroviral treatment: state of the art and future directions.
AIDS (London, England) 1991;5 Suppl 2():S181-8.
1990: Boyle M J; Swanson C E; Turner J J; Thompson I L; Roberts J; Penny R; Cooper D A
Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma.
British journal of haematology 1990;76(4):506-12.
1990: McLaws M L; Brown A R; Cunningham P H; Imrie A A; Wilcken B; Cooper D A
Prevalence of maternal HIV infection based on anonymous testing of neonates, Sydney 1989.
The Medical journal of Australia 1990;153(7):383-6.
1990: Sculley T B; Apolloni A; Hurren L; Moss D J; Cooper D A
Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.
The Journal of infectious diseases 1990;162(3):643-8.
1990: Tindall B; Swanson C E; Cooper D A
Development of AIDS in a cohort of HIV-seropositive homosexual men in Australia.
The Medical journal of Australia 1990;153(5):260-5.
1990: Swanson C E; Cooper D A
Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group.
AIDS (London, England) 1990;4(8):749-57.
1990: McDonald A M; Whyte B M; Jacobs D; Philpot C R; Bradford D L; Monheit B; James M L; Goulden T; Cooper D A; Kaldor J M
Voluntary HIV antibody testing among STD clinic patients: a pilot study.
The Medical journal of Australia 1990;153(1):12-4.
1990: Tindall B; Cotton R; Swanson C; Perdices M; Bodsworth N; Imrie A; Cooper D A
Fifth International Conference on the acquired immunodeficiency syndrome.
The Medical journal of Australia 1990;152(4):204-11, 214.
1990: Bodsworth N; Cooper D A
Ribavirin: a role in HIV infection?
Journal of acquired immune deficiency syndromes 1990;3(9):893-5.
1990: Perdices M; Cooper D A
Neuropsychological investigation of patients with AIDS and ARC.
Journal of acquired immune deficiency syndromes 1990;3(6):555-64.
1989: Brew B J; Perdices M; Darveniza P; Edwards P; Whyte B; Burke W J; Garrick R; O'Sullivan D; Penny R; Cooper D A
The neurological features of early and 'latent' human immunodeficiency virus infection.
Australian and New Zealand journal of medicine 1989;19(6):700-5.
1989: Tindall B; Hing M; Edwards P; Barnes T; Mackie A; Cooper D A
Severe clinical manifestations of primary HIV infection.
AIDS (London, England) 1989;3(11):747-9.
1989: Tindall B; Swanson C; Donovan B; Cooper D A
Sexual practices and condom usage in a cohort of homosexual men in relation to human immunodeficiency virus status.
The Medical journal of Australia 1989;151(6):318-22.
1989: Sculley T B; Apolloni A; Stumm R; Moss D J; Mueller-Lantczh N; Misko I S; Cooper D A
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.
Virology 1989;171(2):401-8.
1989: Perdices M; Cooper D A
Simple and choice reaction time in patients with human immunodeficiency virus infection.
Annals of neurology 1989;25(5):460-7.
1989: Tindall B; Finlayson R; Mutimer K; Billson F A; Munro V F; Cooper D A
Malignant melanoma associated with human immunodeficiency virus infection in three homosexual men.
Journal of the American Academy of Dermatology 1989;20(4):587-91.
1989: Tindall B; Swanson C; Whyte B M; Perdices M; Cooper D A
Fourth International Conference on the acquired immunodeficiency syndrome.
The Medical journal of Australia 1989;150(2):87-92.
1988: Cooper D A; Marriott D J; Harkness J L; Bryant D H
The acquired immunodeficiency syndrome and tuberculosis.
The Medical journal of Australia 1988;149(11-12):714-5.
1988: Whyte B M; Cooper D A
The surveillance definition of the acquired immunodeficiency syndrome and the clinical classification of infection with the human immunodeficiency virus type 1.
The Medical journal of Australia 1988;149(7):368-73.
1988: Sculley T B; Cross S M; Borrow P; Cooper D A
Prevalence of antibodies to Epstein-Barr virus nuclear antigen 2B in persons infected with the human immunodeficiency virus.
The Journal of infectious diseases 1988;158(1):186-92.
1988: Tindall B; Cooper D A; Donovan B; Penny R
Primary human immunodeficiency virus infection. Clinical and serologic aspects.
Infectious disease clinics of North America 1988;2(2):329-41.
1988: Cooper D A; Tindall B; Wilson E J; Imrie A A; Penny R
Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus.
The Journal of infectious diseases 1988;157(5):889-96.
1988: Tindall B; Cooper D A; Donovan B; Barnes T; Philpot C R; Gold J; Penny R
The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men.
Australian and New Zealand journal of medicine 1988;18(1):8-15.
1985: Cooper D A; Gold J; Maclean P; Donovan B; Finlayson R; Barnes T G; Michelmore H M; Brooke P; Penny R
Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion.
Lancet 1985;1(8428):537-40.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

David Cooper

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Procedures

Concepts & Ideas

Geographic Areas

Anatomy

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of David Cooper (preview)

All Publications